Rallybio Corp
For the period ended Sep 30, 2024. Filed Nov 7, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 7, 2024
RLYB$15.76+0.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Unaudited Condensed Consolidated Statements of Changes in Stockholders' Equity
Condensed Consolidated Statements of Changes in Stockholders' Equity
| FOR THE THREE MONTHS ENDED SEPTEMBER 30, 2024 AND 2023 · COMMON · ADDITIONAL PAID-INCAPITAL · ACCUMULATED DEFICIT · ACCUMULATED OTHER COMPREHENSIVE GAIN (LOSS) · STOCKHOLDERS' EQUITY | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| (in thousands, except share amounts) · SHARES · AMOUNT | |||||||||||
| June 30, 2023 | 37,790,856 | $4 | $336,154 | $(196,629) | $(272) | $139,257 | |||||
| Share-based compensation expense | — | — | 2,634 | — | — | 2,634 | |||||
| Issuance of common stock under the stock award plan | 10,000 | — | — | — | — | — | |||||
| Net loss | — | — | — | (18,374) | — | (18,374) | |||||
| Other comprehensive gain | — | — | — | — | 64 | 64 | |||||
| Balance, September 30, 2023 | 37,800,856 | $4 | $338,788 | $(215,003) | $(208) | $123,581 | |||||
| June 30, 2024 | 41,487,586 | $4 | $350,594 | $(270,510) | $(71) | $80,017 | |||||
| Share-based compensation expense | — | — | 2,027 | — | — | 2,027 | |||||
| Net loss | — | — | — | (11,466) | — | (11,466) | |||||
| Other comprehensive gain | — | — | — | — | 240 | 240 | |||||
| Balance, September 30, 2024 | 41,487,586 | $4 | $352,621 | $(281,976) | $169 | $70,818 | |||||
| FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2024 AND 2023 · COMMON · ADDITIONAL PAID-INCAPITAL · ACCUMULATED DEFICIT · ACCUMULATED OTHER COMPREHENSIVE GAIN (LOSS) · STOCKHOLDERS' EQUITY | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| (in thousands, except share amounts) · SHARES · AMOUNT | |||||||||||||||
| December 31, 2022 | 37,837,369 | $4 | $330,208 | $(160,681) | $(214) | $169,317 | |||||||||
| Share-based compensation expense | — | — | 8,371 | — | — | 8,371 | |||||||||
| Issuance of common stock under the stock award plan | 11,219 | — | — | — | — | — | |||||||||
| Issuance of common stock under the stock purchase plan | 43,423 | — | 209 | — | — | 209 | |||||||||
| Forfeiture of restricted common stock | (91,155) | — | — | — | — | — | |||||||||
| Net loss | — | — | — | (54,322) | — | (54,322) | |||||||||
| Other comprehensive gain | — | — | — | — | 6 | 6 | |||||||||
| Balance, September 30, 2023 | 37,800,856 | $4 | $338,788 | $(215,003) | $(208) | $123,581 | |||||||||
| December 31, 2023 | 37,829,565 | $4 | $341,410 | $(235,245) | $15 | $106,184 | |||||||||
| Share-based compensation expense | — | — | 6,030 | — | — | 6,030 | |||||||||
| Issuance of common stock upon completion of a securities purchase agreement, net of offering costs of $268 | 3,636,363 | — | 5,137 | — | — | 5,137 | |||||||||
| Issuance of common stock under the stock award plan | 1,925 | — | — | — | — | — | |||||||||
| Issuance of common stock under the stock purchase plan | 38,289 | — | 44 | — | — | 44 | |||||||||
| Forfeiture of restricted common stock | (18,556) | — | — | — | — | — | |||||||||
| Net loss | — | — | — | (46,731) | — | (46,731) | |||||||||
| Other comprehensive gain | — | — | — | — | 154 | 154 | |||||||||
| Balance, September 30, 2024 | 41,487,586 | $4 | $352,621 | $(281,976) | $169 | $70,818 | |||||||||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.